BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/15/2025 9:46:05 AM | Browse: 16 | Download: 36
 |
Received |
|
2025-04-18 03:09 |
|
Peer-Review Started |
|
2025-04-18 07:34 |
|
First Decision by Editorial Office Director |
|
2025-05-12 04:29 |
|
Return for Revision |
|
2025-05-12 04:29 |
|
Revised |
|
2025-08-13 08:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-23 02:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-23 09:40 |
|
Articles in Press |
|
2025-10-23 09:40 |
|
Edit the Manuscript by Language Editor |
|
2025-10-30 17:07 |
|
Typeset the Manuscript |
|
2025-12-04 01:44 |
|
Publish the Manuscript Online |
|
2025-12-15 09:46 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Rheb1 signaling and the fate of pancreatic β-cells: Toward a new frontier in diabetes therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hadi Karimkhani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hadi Karimkhani, Assistant Professor, PhD, Medical Biochemistry, İstanbul Okan University, Tepeören Mahallesi Tuzla Kampüsü, İstanbul 34959, Tuzla, Türkiye. drhadi.h@gmail.com |
| Key Words |
Pancreatic β-cell fate; Rheb1 signaling; MTOR pathway; Diabetes therapy; Β-cell survival |
| Core Tip |
Rheb1 is a critical regulator of pancreatic β-cell survival and insulin secretion, acting through the mTORC1 pathway to support β-cell mass and function. This invited commentary evaluates how Rheb1-driven signaling modulates β-cell fate and assesses its promise as a therapeutic target in diabetes. While enhancing Rheb1 activity could preserve or expand functional β-cell mass, careful modulation is required to avoid unintended effects such as α-cell overactivity. Understanding the dualistic nature of Rheb1 signaling in islet cell populations will be key to harnessing this pathway for future diabetes treatments. |
| Publish Date |
2025-12-15 09:46 |
| Citation |
Karimkhani H. Rheb1 signaling and the fate of pancreatic β-cells: Toward a new frontier in diabetes therapy. World J Diabetes 2025; 16(12): 108609 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i12/108609.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i12.108609 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
